Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 3, 2011, Pages 287-295

  Lawn, S D ^a,b   Ayles, H ^a,c   Egwaga, S ^d   Williams, B ^e   Mukadi, Y D ^f   Santos Filho, E D ^g   Godfrey Faussett, P ^a   Granich, R M ^h   Harries, A D ^a,i  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c UNIVERSITY OF ZAMBIA   (Zambia)

^d National Tuberculosis Programme   (Tanzania)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f FAMILY HEALTH INTERNATIONAL   (United States)

^g Parceria Brasileira Contra A Tuberculose (Stop TB Brazil)   (Brazil)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Africa; Empirical treatment; HIV; Mortality; Tuberculosis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; COTRIMOXAZOLE; EFAVIRENZ; NEVIRAPINE; RIFAMPICIN; STAVUDINE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BACTERIAL TRANSMISSION; BOTSWANA; CD4+ T LYMPHOCYTE; COUGHING; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG TOLERABILITY; EPIDEMIC; FEVER; GRAM POSITIVE INFECTION; HEALTH PROGRAM; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; LESOTHO; LIVER TOXICITY; MALAWI; MASS SCREENING; MORBIDITY; MORTALITY; MOZAMBIQUE; MYCOBACTERIUM TUBERCULOSIS; NAMIBIA; NEUROPATHY; NIGHT SWEAT; PATIENT COMPLIANCE; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS PNEUMONIA; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGNOSIS; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SEPSIS; SEROPREVALENCE; SOUTH AFRICA; SURVIVAL; SWAZILAND; THERAPY DELAY; TUBERCULOSIS; TUBERCULOSIS CONTROL; WEIGHT REDUCTION; ZAMBIA; ZIMBABWE;

AFRICA SOUTH OF THE SAHARA; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CROSS INFECTION; HIV INFECTIONS; HUMANS; TUBERCULOSIS;

EID: 79951608523     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. United Nations. The Millennium Development Goals report 2008. New York, NY, USA: United Nations, 2008. http://www.un.org/millenniumgoals/ Accessed February 2010.
2. World Health Organization. Global tuberculosis control. A short update to the 2009 report. Geneva, Switzerland: WHO, 2009. http://www.who.int/tb/ publications/global-report/2009/update/tbu-9.pdf Accessed March 2010.
3. World Health Organization. Strategic framework to decrease the burden of TB/HIV. WHO/CDS/TB/2002.296 WHO/HIV-AIDS/2002.2. Geneva, Switzerland: WHO, 2002. http://www.who.int/tb/publications/who-cds-tb-2002-296/en/index.html Accessed February 2010.
4. World Health Organization. WHO Three I's meeting. Report of a joint WHO HIV/AIDS and TB Department meeting. Geneva, Switzerland: WHO, 2008. http://www.who.int/hiv/pub/meeting reports/WHO-3Is-meeting-report.pdf Accessed February 2010.
5. Lawn S D, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. Clin Chest Med 2009; 30: 685-699.
6. Harries A D, Zachariah R, Corbett E L, et al. Confronting the HIV-associated tuberculosis epidemic - when will we act? Lancet 2010; 375: 1906-1919.
7. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152. (Pubitemid 32142288)
8. Ackah A N, Coulibaly D, Digbeu H, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Cote d'Ivoire. Lancet 1995; 345: 607-610.
9. Greenberg A E, Lucas S, Tossou O, et al. Autopsy-proven causes of death in HIV-infected patients treated for tuberculosis in Abidjan, Cote d'Ivoire. AIDS 1995; 9: 1251-1254.
10. Wiktor S Z, Sassan-Morokro M, Grant A D, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-1475. (Pubitemid 29204364)
11. Grimwade K, Sturm A W, Nunn A J, Mbatha D, Zungu D, Gilks C F. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005; 19: 163-168. (Pubitemid 40409534)
12. Dheda K, Lampe F C, Johnson M A, Lipman M C. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-1676. (Pubitemid 39411018)
13. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 42-46. (Pubitemid 44306486)
14. World Health Organization. Global tuberculosis control 2009. Epidemiology, strategy, financing. WHO/HTM/TB/2009.411. Geneva, Switzerland: World Health Organization, 2009. http://www.who.int/tb/publications/global- report/2009/pdf/full-report.pdf Accessed January 2010.
15. World Health Organization. WHO declares TB an emergency in Africa. Call for 'urgent and extraordinary actions' to halt a worsening epidemic. Geneva, Switzerland: WHO, 2005. http://www.who.int/mediacentre/news/2005/africa- emergency/en/ Accessed September 2005.
16. Lawn S D, Bekker L G, Middelkoop K, Myer L, Wood R. Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis 2006; 42: 1040-1047.
17. Middelkoop K, Bekker L G, Myer L, Dawson R, Wood R. Rates of tuberculosis transmission to children and adolescents in a community with a high prevalence of HIV infection among adults. Clin Infect Dis 2008; 47: 349-355. (Pubitemid 352009354)
18. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175: 87-93. (Pubitemid 46105314)
19. Bradshaw D, Laubscher R, Dorrington R, Bourne D E, Timaeus I M. Unabated rise in number of adult deaths in South Africa. S Afr Med J 2004; 94: 278-279. (Pubitemid 38585220)
20. Kranzer K, Houben R M, Glynn J R, Bekker L G, Wood R, Lawn S D. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 93-102.
21. Lawn S D, Myer L, Bekker L G, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612. (Pubitemid 44162402)
22. Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21: 713-719. (Pubitemid 46568628)
23. Bonnet M M, Pinoges L L, Varaine F F, et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 2006; 20: 1275-1279. (Pubitemid 44030376)
24. Lawn S D, Myer L, Edwards D, Bekker L G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23: 1717-1725.
25. Lawn S D, Kranzer K, Edwards D J, McNally M, Bekker L G, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pre-treatment screening strategy. AIDS 2010; 24: 1323-1328.
26. Lawn S D, Edwards D J, Kranzer K, Vogt M, Bekker L G, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23: 1875-1880.
27. Bassett I, Chetty S, Wang B, et al. Intensive TB screening for HIV-infected patients ready to start ART in Durban, South Africa: limitations of WHO guidelines. Program and Abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada: CRIO, February 2009. [Abstract #779]
28. Lucas S B, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7: 1569-1579. (Pubitemid 24008849)
29. Lucas S B, De Cock K M, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308: 1531-1533.
30. Rana F S, Hawken M P, Mwachari C, et al. Autopsy study of HIV-1-positive and HIV-1-negative adult medical patients in Nairobi, Kenya. J Acquir Immune Defic Syndr 2000; 24: 23-29. (Pubitemid 30447802)
31. Ansari N A, Kombe A H, Kenyon T A, et al. Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 2002; 6: 55-63. (Pubitemid 34263546)
32. Kritzinger F E, Den B S, Verver S, et al. No decrease in annual risk of tuberculosis infection in endemic area in Cape Town, South Africa. Trop Med Int Health 2009; 14: 136-142.
33. Chapman A L, Munkanta M, Wilkinson K A, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. AIDS 2002; 16: 2285-2293. (Pubitemid 35449014)
34. Wood R, Liang H, Wu H, et al. Changing prevalence of tuberculosis infection with increasing age in high-burden townships in South Africa. Int J Tuberc Lung Dis 2010; 14: 406-412.
35. Shanaube K, Sismanidis C, Ayles H, et al. Annual risk of tuberculous infection using different methods in communities with a high prevalence of TB and HIV in Zambia and South Africa. PLoS One 2009; 4: e7749.
36. Braitstein P, Brinkhof M W, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817-824.
37. Lawn S D, Harries A D, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22: 1897-1908.
38. Lawn S D, Myer L, Orrell C, Bekker L G, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19: 2141-2148. (Pubitemid 41669003)
39. Bassett I V, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51: 135-139.
40. Getahun H, Kittikraisak W, Heilig C M, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8(1): e1000391.
41. Reid M J, Shah N S. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9: 173-184.
42. Dawson R, Masuka P, Edwards D J, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14: 52-58.
43. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049. (Pubitemid 46908825)
44. Perkins M D, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007; 196 (Suppl 1): S15-S27. (Pubitemid 47206081)
45. World Health Organization. The use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Geneva, Switzerland: WHO, 2007. http://www.who.int/tb/dots/laboratory/ Use%20of%20Liquid%20TB%20Culture-Summary%20Report.pdf Accessed November 2010.
46. Shah M, Variava E, Holmes C B, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 50: 537-545.
47. World Health Organization. Improving the diagnosis and treatment of smear-negative pulmonary and extra-pulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. WHO/HTM/2007.379 WHO/HIV/2007.1. Geneva, Switzerland: WHO, 2007. http://whqlibdoc.who.int/hq/2007/WHO-HTM-TB-2007.379-eng.pdf Accessed February 2010.
48. Holmes C B, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006; 42: 464-469. (Pubitemid 44050895)
49. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359: 2059-2064. (Pubitemid 34680968)
50. Williams B G, Dye C. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 2003; 301: 1535-1537. (Pubitemid 37128545)
51. Lawn S D, Little F, Bekker L G, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009; 23: 335-342.
52. Innes C, Charalambous S, Felix M, et al. The effectiveness of isoniazid preventive therapy in reducing mortality in patients on antiretroviral therapy. Abstracts of the 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, USA. February 2010. [Abstract no. 102]
53. Lawn S D, Bekker L G, Miller R F. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5: 361-373. (Pubitemid 40779257)
54. Lawn S D, Myer L, Bekker L G, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21: 335-341. (Pubitemid 46175045)
55. Lawn S D, Wilkinson R J, Lipman M C, Wood R. Immune reconstitution and 'unmasking' of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177: 680-685. (Pubitemid 351490554)
56. Bock N N, Jensen P A, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196 (Suppl 1): S108-S113. (Pubitemid 47206089)
57. Gandhi N R, Moll A, Sturm A W, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368: 1575-1580. (Pubitemid 44780738)
58. Kucers A, Crowe S M, Grayson M L, Hoy J F. The use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs, 5th ed. Oxford, UK: Butterworth-Heinemann, 1997.
59. Anglaret X, Messou E, Ouassa T, et al. Pattern of bacterial diseases in a cohort of HIV-1 infected adults receiving cotrimoxazole prophylaxis in Abidjan, Cote d'Ivoire. AIDS 2003; 17: 575-584. (Pubitemid 36293111)
60. Boulle A, Van C G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300: 530-539.
61. Westreich D J, Sanne I, Maskew M, et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009; 48: 1617-1623.
62. Hoffmann C J, Charalambous S, Thio C L, et al. Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS 2007; 21: 1301-1308. (Pubitemid 46883484)
63. World Health Organization. Rapid advice. Antiretroviral therapy for HIV infection in adults and adolescents. Geneva, Switzerland: WHO, 2009. http://www.who.int/hiv/pub/arv/rapid-advice-art.pdf Accessed January 2010.